Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.
Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.
In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).